Thiruvananthapuram: Researchers at the Biotechnology Center of Rajiv Gandhi (RGCB) here have identified Cyclophilin A, protein which is a player known in some human diseases, as a potential drug target to reduce the risk of heart disease in patients with diabetes.
“Patients with diabetes mellitus on an increased risk of vascular disease and vulnerable to broken.
Our research has shown that Cyclophilin A plays a major role in increasing risk, “said Dr.
Surya Ramachandran, a program scientist with cardiovascular disease and diabetes biology lab, RGCB.
The findings of this study were recently published in cells, international biology journals.
Results Attack of the outbrave of cholesterol plaque stored on the arterial wall.
Tears or broken in plaques will activate the repair mechanism that results in blood clots.
Like it can completely block the flow of blood to the heart muscle and cause a heart attack.
Ibribe cyclophilin A will have potential use in Reducing the vulnerability of a heart attack because of the rupture of placards.
This is also being developed as a clinical serological marker detecting vascular inflammation in patients with diabetes, he said.
This will help in the detection of the risks and development of new pharmacological therapy.
“Cyclophilin protein A damaged the process of cleaning Han cells are fast and efficient that have been programmed to die, resulting in rapid development of plaque formation in patients with type 2 diabetes mellitus, “said Dr.
Ramachandran.